Blood test for detecting BRAF mutation in melanoma
Part of Cancer, Skin clinical trials.
This trial tests a new blood test to detect a specific gene change (BRAF V600E) in melanoma that has come back. The test uses a technology called CRISPR to find the mutation in a simple blood draw, which could help guide treatment without needing a tissue biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of melanoma (a type of skin cancer).
- Your melanoma must have come back (relapsed) and not be removable with surgery.
- Your doctor must already know whether your melanoma has a BRAF mutation (a specific gene change).
- You must be able to give a blood sample for testing.
- You cannot be pregnant or breastfeeding, and you must not have a very short life expectancy (less than 3 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why some people with a specific type of colorectal cancer (BRAF V600E-mutated) stop responding to targeted drugs over time. Researchers will take small tissue samples before and during your treatment with anti-EGFR antibody and BRAF inhibitor to understand resistance and help improve future treatments.
This trial studies a very sensitive blood test to detect melanoma-related genetic changes in people with BRAF V600E. It may help track the disease more closely and guide care in advanced or high-risk situations.
This study looks at your melanoma's gene activity and a blood test for tumor DNA to help predict the risk of the cancer coming back. You will need to provide blood and tissue samples, and the goal is to find better ways to personalize treatment for people with thicker, high-risk melanomas.
This study follows people with BRAF V600E–positive metastatic colorectal (colon) cancer to better understand how the cancer’s biology changes over time. It may help researchers learn which features to watch and how this cancer behaves after initial treatment.
This study tests if giving you targeted therapy pills (encorafenib and binimetinib) only when a blood test shows your cancer is active — instead of continuously — can help keep the melanoma under control with fewer side effects. It is designed for people with advanced melanoma that has a BRAF mutation.
This Phase 1 trial tests a combination of targeted cancer medicines to treat melanoma that has spread or cannot be removed by surgery. It is for people whose tumor has a specific BRAF mutation, and who have either stayed stable on a prior targeted treatment or no longer respond to it.
Hear when a new BRAF V600E Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.